David DeNardo
Washington University in St. Louis
H-index: 51
North America-United States
Top articles of David DeNardo
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
“RIPping” off Pancreas Cancer's Blockage of Immune Surveillance | Cancer Discovery | Xiuting Liu Blake E Sells David G DeNardo | 2024/2/8 |
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression | Cancer discovery | Jiayu Ye John M Baer Douglas V Faget Vasilios A Morikis Qihao Ren | 2024/4/17 |
Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough | Clinical Cancer Research | Varintra E Lander David G DeNardo | 2024/2/1 |
Targeting IL-1β mitigates radiation induced MDSC expansion & improves survival in glioblastoma | Cancer Research | Subhajit Ghosh Jiayi Huang David DeNardo Dennis Hallahan Jerry Jaboin | 2024/3/22 |
Abstract C003: RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma | Cancer Research | Kian-Haut Lim Manuel Hidalgo Mark H O'Hara Kristen R Spencer Ignacio Garrido-Laguna | 2024/1/16 |
Tumor-associated fibrosis leads to an increase in T-cell exhaustion and impairs tumor control in non-small cell lung cancer | Cancer Research | Usman Y Panni Varun Shenoy Brett Knolhoff Faiz Ahmed Brett Herzog | 2024/3/22 |
Abstract A091: The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D … | Cancer Research | Silvia Coma Xiuting Liu Noah L Pieper Wen-Hsuan Chang Kirsten L Bryant | 2024/1/16 |
Combined inhibition of RAF, MEK and FAK increases PDAC responsiveness to cytotoxic-and immune therapy | Cancer Research | Xiuting Liu John Baer Brett Knolhoff Graham Hogg Faiz Ahmad | 2024/3/22 |
Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma | OncoImmunology | Vikram S Pothuri Graham D Hogg Leah Conant Nicholas Borcherding C Alston James | 2024/12/31 |
sc2MeNetDrug: A computational tool to uncover inter-cell signaling targets and identify relevant drugs based on single cell RNA-seq data | PLoS computational biology | Jiarui Feng S Peter Goedegebuure Amanda Zeng Ye Bi Ting Wang | 2024/1/5 |
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer | Nature Communications | Ashenafi Bulle Peng Liu Kuljeet Seehra Sapana Bansod Yali Chen | 2024/3/20 |
Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer | Cancer discovery | Jad I Belle Devashish Sen John M Baer Xiuting Liu Varintra E Lander | 2024/4/29 |
Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma | ACS Pharmacology & Translational Science | Xiaohui Zhang Lisa Detering Gyu Seong Heo Deborah Sultan Hannah Luehmann | 2023/12/5 |
Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized … | Cancer Research | Andrew A Davis Leonel Hernandez-Aya Jingqin Luo Mateusz Opyrchal Foluso O Ademuyiwa | 2023/3/1 |
Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non–small cell lung cancer | Science translational medicine | Brett H Herzog John M Baer Nicholas Borcherding Natalie L Kingston Jad I Belle | 2023/6/7 |
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology | Cancer Immunology, Immunotherapy | Usman Y Panni Michael Y Chen Felicia Zhang Darren R Cullinan Lijin Li | 2023/8 |
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study | Clinical Cancer Research | Andrea Wang-Gillam Kian-Huat Lim Robert McWilliams Rama Suresh Albert C Lockhart | 2023/11/14 |
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma | Science translational medicine | Subhajit Ghosh Jiayi Huang Matthew Inkman Jin Zhang Sukrutha Thotala | 2023/1/25 |
p38MAPKα stromal reprogramming sensitizes metastatic breast cancer to immunotherapy | Cancer discovery | Douglas V Faget Xianmin Luo Matthew J Inkman Qihao Ren Xinming Su | 2023/6/2 |
Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction | Blood, The Journal of the American Society of Hematology | Mehmet Emrah Selli Jack H Landmann Marina Terekhova John Lattin Amanda Heard | 2023/6/29 |
